Latest Conference Articles

At SDPA, Swanson highlighted a variety of key tips for clinicians, including strategies for treating hemangiomas and warts in children.

Analysis of plasma EVs identified 448 proteins associated with islet autoimmunity and potential early T1D biomarkers.

Alan Hutchison, MD, PhD, and Mishal Ali discuss the substantially increased risk of long-term mortality caused by diabetes in patients undergoing major organ transplants.

This Q&A interview highlights ways to counsel patients regarding the safety of various sunscreens, photoprotection, and UV radiation's impact on skin cancer.

New systematic review of 7012 kidney transplant recipients with T2D finds GLP-1 receptor agonists cut major adverse kidney events and mortality by 61%.

New data from ENDO 2026 reflect the accompanying reductions in HbA1c, lipids, and other major biomarkers in patients treated with GLP-1 RAs.

New data from ENDO 2026 have indicated a statistically significant increase in hypotension and related events in adults receiving GLP-1s who are already hypertensive.

This interview at the SDPA Summer Conference highlights the environment and climate change's impact on skin health and triggers of different conditions.

MiniMed 780G improved HbA1c and time in range in real-world diabetes data presented at ENDO 2026, with minimal hypoglycemia risk.

This SDPA interview with Steven Daveluy, MD, highlights integrative dermatology practices, acne strategies, and the value of supplements and dietary changes.

This discussion of integrative dermatology highlights ways to combine conventional medicine and complementary or alternative medicine.

Catch up on any data and key clinician perspectives presented at the American Diabetes Association Scientific Sessions 2026.

In this SDPA Summer Dermatology Meeting interview, Zirwas speaks on treatment gaps for dermatologic conditions and off-label alternatives.

Fonseca discusses substantially lower persistence and adherence with GLP-1s in real-world practice, highlighting methods for clinicians to address this.

This SDPA Summer 2026 talk highlights off-label treatment tips for dermatology clinicians in conditions such as alopecia areata, morphea, and different genital conditions.

This episode covers recently released data regarding the Dexcom G7 and Eli Lilly’s investigational triple agonist retatrutide from ADA 2026.

Jose Arias Jr., MD, discusses GINA 2025 criteria, ICS initiation, device education, and distinguishing viral wheezing from early asthma in children under 5 years.

Shaminie Athinarayanan, PhD, discusses her recent study investigating the role of carbohydrate reduction in patients with obesity currently going through menopause.

This preview of the 2026 SDPA Summer Dermatology Conference highlights different sessions and interviews covered by the HCPLive team.

Lance Sloan, MD, discusses his recent sub-analysis of the CATALYST trial, investigating whether hypercortisolism limits the efficacy of GLP-1s.

Sarath Raju, MD, discussed a study that found persistent IR was associated with higher ground glass opacity on CT, suggesting metabolic inflammation may drive early ILD development.

Functional air trapping in emphysematous lung regions may predict pneumothorax after BLVR, per ATS 2026 data presented by Isam Albaba, MBBS, from Temple University.

Amit Gupta, MBBS, DNB, joins the show to discuss diabetes treatment in a traditionally underserved population and to address the IDF’s work in moving it forward.

Payel Gupta, MD, discusses how IgE, FeNO, and type 2 comorbidities inform biologic choice and when a lack of response warrants switching agents.

Sparrow Pharmaceuticals presented phase 2a data for the HSD-1 inhibitor clofutriben at ADA 2026.

Phase 2 findings presented at ATS 2026 by Gerald Criner, MD, show pegtarazimod cut supplemental oxygen needs in hospitalized AE-COPD patients for up to 60 days.

At ATS 2026, Robert Wallis, MD, discussed PanTB-HM findings on FEV1 recovery and NAC antimicrobial interactions.

Ketan Dhatariya, MD, PhD, MS, joins the show to discuss how therapies for diabetes have evolved in the UK in comparison to the US.